Compare KE Holdings Inc (BEKE) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KE Holdings Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? KE Holdings Inc trades at $17.28 (market cap $18.92B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B). The key difference: KE Holdings Inc is far larger — about 2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and KE Holdings Inc pays a 1.63% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BEKE | BIO | |
|---|---|---|
Market Cap | $18.92B | $9.43B |
Sector | Technology | Health |
52-Week High | $20.36 | $356.25 |
52-Week Low | $14.26 | $241.71 |
Enterprise Value | $14.66B | $9.18B |
Dividend Yield | 1.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KE Holdings Inc
KE Holdings (Beike) is China’s leading platform for housing transactions and services. It operates the Lianjia brand and uses data-driven technology to facilitate home sales, rentals, and home renovation services.
Read more on BEKE →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
